Início › Linfoma Difuso de Grandes Células B › Utah
Ensaios clínicos de Linfoma Difuso de Grandes Células B em Utah
14 estudos para Linfoma Difuso de Grandes Células B estão buscando participantes em locais em Utah.
Cidades em Utah
Texto oficial do estudo (Inglês)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Intermountain Medical Center ( Site 0182), Murray
- Intermountain Healthcare - St. George ( Site 0203), St. George
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06890884A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Community Cancer Trials of Utah, Ogden
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Intermountain Healthcare, Salt Lake City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
RecrutandoFase 1/2
6 Months – 25 Years · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- Intermountain Health LDS Hospital, Salt Lake City
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 31 de ago. de 2026 · NCT06500273Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
- Huntsman Cancer Institute, Salt Lake City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT06227026Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT07188558Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de jul. de 2026 · NCT05077527External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
- Huntsman Cancer Institute at University of Utah, Salt Lake City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 4 de jun. de 2026 · NCT07528352A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 20 de mar. de 2026 · NCT04830137Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT04775745Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 20 de out. de 2025 · NCT05890352Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 26 de set. de 2024 · NCT06238648Fonte: ClinicalTrials.gov, dados obtidos em 2 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.